VirNext provides a large panel of solutions and deliverables in the fields of viral production (see virus production) and evaluation of anti-viral compounds (see drug evaluation). For more information please contact us.

Viral quantification and fitness


  • Quantification of infectious viral particles: plaque assay (PFU)
  • End-point dilution quantification: 50% tissue cell infectious dose  (TCID50) assay or 50% eggs infectious dose  (EID50) assay
  • Quantification by the capacity to aggregate red blood cells : hemagglutination (HA) assay.
  • Evaluation of influenza neuraminidase enzymatic activity: fluorometric neuraminidase inhibition (NAI) Assay
  • Viral antigen quantification: single radial immuno-diffusion (SRID) assay
  • Enzyme-linked immunosorbent assay (ELISA)

Vaccine response assays


  • Immunization and infectious challenge (mice and ferrets)
  • Protection assay
  • Humoral response characterization: microneutralization (MN) and hemagglutination inhibition assays (HAI)
  • Viral titration (nasal wash and lung)
  • Cytokine evaluation

Evaluation of candidate compounds


 

VirNext offers in vitro and in vivo evaluation of antiviral or proviral properties of candidate compounds. Molecules can be evaluated on a large panel of human and animal influenza viruses. See drug evaluation